The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
Research Question:
Does the drug Inebilizumab improve disability in patients with a particular type of
encephalitis, called anti-N-methyl-D-aspartate receptor encephalitis?
Basic Study Information
Purpose:
Anti-N-methyl-D-aspartate receptor encephalitis is a life-threatening autoimmune disorder
for which there are no approved therapies. This study will determine if the drug,
Inebilizumab, will improve the disability of patients who have anti-N-methyl-D-aspartate
receptor encephalitis. You will be randomized to receive either standard care for
this disease, Inelbilizumab, or a placebo. You may be eligible to join if you are
18 years of age or older, have a diagnosis of anti-N-methyl-D-aspartate receptor encephalitis,
and have had a recent change in your mental status.
Location: University of Rochester
Study Web URL: https://neuronext.org/projects/nn111-extinguish
Study Reference #: STUDY00006222
Lead Researcher (Principal Investigator)
Lead Researcher:
Andrew Goodman
Study Contact Information
Study Coordinator: Christine Anne
Phone: (585) 276-3037
Email: Christine_annis@urmc.rochester.edu
Additional Study Details
Learn More About These Conditions
More information about Encephalitis
More information about Encephalitis, Viral
Trial Not Found
The study you are looking for is not active at this time.
Return to Search